Protara Therapeutics (TARA) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Protara Therapeutics (TARA) has outperformed Voyager Therapeutics (VYGR) over the past year, losing 46.3% versus a loss of 47.8%. Over five years, VYGR leads with a -39.8% price change compared with -62.1% for TARA. Protara Therapeutics is the larger company by market cap ($153.1 million vs $152.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TARA | VYGR |
|---|---|---|
| Share price | $2.59 | $2.47 |
| Market cap | $153.06M | $152.20M |
| 1-day change | +1.37% | +0.41% |
| YTD return | -51.41% | -37.15% |
| 1-year return | -46.27% | -47.78% |
| 5-year return | -62.13% | -39.76% |
| EPS (TTM) | $-1.36 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.82 | $5.55 |
| 52-week low | $2.51 | $2.39 |
| Distance from 52-week high | -66.88% | -55.50% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +892.66% | +502.83% |
| Average volume | 804.10K | 566.47K |
| Shares outstanding | 59.10M | 61.62M |
| Employees | 46 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
TARA vs VYGR FAQ
Which is bigger, Protara Therapeutics or Voyager Therapeutics?
Protara Therapeutics (TARA) is larger, with a market capitalization of $153.06M compared with $152.20M for Voyager Therapeutics (VYGR).
Which stock has performed better over the past year, TARA or VYGR?
TARA returned -46.27% over the past 12 months, compared with -47.78% for VYGR (price return, excluding dividends). Past performance does not predict future results.
Are Protara Therapeutics and Voyager Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.